Equities research analysts expect that Compugen (NASDAQ:CGEN) will report earnings of ($0.20) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Compugen’s earnings, with estimates ranging from ($0.21) to ($0.19). Compugen posted earnings of ($0.17) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 17.6%. The company is scheduled to announce its next quarterly earnings results on Tuesday, May 8th.
On average, analysts expect that Compugen will report full year earnings of ($0.75) per share for the current financial year, with EPS estimates ranging from ($0.85) to ($0.64). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.80) per share, with EPS estimates ranging from ($1.02) to ($0.57). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Compugen.
Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported ($0.18) EPS for the quarter.
Several research analysts have commented on CGEN shares. Zacks Investment Research downgraded Compugen from a “buy” rating to a “hold” rating in a report on Monday, January 22nd. CIBC assumed coverage on Compugen in a research report on Thursday, March 29th. They set an “outperform” rating on the stock. Oppenheimer assumed coverage on Compugen in a research report on Thursday, March 29th. They set an “outperform” rating and a $9.00 target price on the stock. Finally, ValuEngine cut Compugen from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $8.92.
CGEN opened at $4.40 on Thursday. Compugen has a 52 week low of $2.25 and a 52 week high of $5.40.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new stake in Compugen during the 4th quarter valued at $192,000. Anson Funds Management LP bought a new stake in Compugen during the 4th quarter valued at $281,000. Paloma Partners Management Co bought a new stake in Compugen during the 4th quarter valued at $105,000. Renaissance Technologies LLC boosted its position in Compugen by 26.5% during the 4th quarter. Renaissance Technologies LLC now owns 340,008 shares of the biotechnology company’s stock valued at $850,000 after acquiring an additional 71,308 shares in the last quarter. Finally, ARK Investment Management LLC boosted its position in Compugen by 95.9% during the 4th quarter. ARK Investment Management LLC now owns 2,253,416 shares of the biotechnology company’s stock valued at $5,634,000 after acquiring an additional 1,103,384 shares in the last quarter. 21.17% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Compugen (CGEN) Expected to Announce Earnings of -$0.20 Per Share” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/compugen-cgen-expected-to-announce-earnings-of-0-20-per-share.html.
Compugen Company Profile
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations.
Get a free copy of the Zacks research report on Compugen (CGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.